Academic literature on the topic 'In-Vitro Testing of Quick Dissolving Tablets'

This research aimed to develop innovative self-nanoemulsifying chewable tablets (SNECT) to increase oral bioavailability of tadalafil (TDL), a nearly insoluble phosphodiesterase-5 inhibitor. Cinnamon essential oil, PEG 40 hydrogenated castor oil (Cremophor® RH 40), and polyethylene glycol 400 served as the oil, surfactant, and cosurfactant in the nanoemulsifying system, respectively. Primary liquid self-nanoemulsifying delivery systems (L-SNEDDS) were designed using phase diagrams and tested for dispersibility, droplet size, self-emulsifying capability, and thermodynamic stability. Adsorption on a carrier mix of silicon dioxide and microcrystalline cellulose was exploited to solidify the optimum L-SNEDDS formulation as self-nanoemulsifying granules (SNEG). Lack of crystalline TDL within the granules was verified by DSC and XRPD. SNEG were able to create a nanoemulsion instantaneously (165 nm), a little larger than the original nanoemulsion (159 nm). SNECT were fabricated by compressing SNEG with appropriate excipients. The obtained SNECT retained their quick dispersibility dissolving 84% of TDL within 30 min compared to only 18% dissolution from tablets of unprocessed TDL. A pharmacokinetic study in Sprague–Dawley rats showed a significant increase in Cmax (2.3-fold) and AUC0–24 h (5.33-fold) of SNECT relative to the unprocessed TDL-tablet (p < 0.05). The stability of TDL-SNECT was checked against dilutions with simulated GI fluids. In addition, accelerated stability tests were performed for three months at 40 ± 2 °C and 75% relative humidity. Results revealed the absence of obvious changes in size, PDI, or other tablet parameters before and after testing. In conclusion, current findings illustrated effectiveness of SNECT to enhance TDL dissolution and bioavailability in addition to facilitating dose administration.

The development of dosage forms that are easy to manufacture and administer, as well as rapid release and increased bioavailability, have led to new drug delivery systems. To achieve the desired result, drugs must be delivered to the site of action at a speed and concentration that maximizes therapeutic benefits and minimizes side effects. The most popular and efficient way of drug administration is oral. Recently, many medicinal products have been released in the market. The use of lyophilizers and oral tablets or films have expanded treatment options. Both children and adults can benefit from advantages such as ease of operation and ease of use. This study focuses on oral tablets, a new approach in drug delivery systems that is increasingly gaining attention in the manufacturing industry. Due to the highly disintegrating ingredients in the formulation, an orally disintegrating tablet dissolves in the mouth in about a minute with saliva without the need to drink water. This study focuses on currently available technologies and advances in orodispersible tablet formulation. In addition to traditional manufacturing methods, this review presents some new technologies such as freeze-drying, direct compression, slab casting, shrinking and quick-melting film, and their advantages and disadvantages. their weakness. Many researchers have developed breakout boards using proprietary technologies such as Zydis, wow tab, flash tab, Oroquick and Orosolv. It applies to hardness, brittleness, wet time, moisture absorption, Disintegration, dissolution testing and other solids dosage forms measurements.

INTRODUCTION: Efficacy of on-demand nonhormonal contraception that targets and disables progressively motile sperm (PMS) can be studied through surrogate postcoital testing (PCT) in sheep models, due to similarities to human reproductive tract size and anatomy. We utilized PCT to assess the contraceptive potential of anti-sperm antibody in tablet form in vivo in sheep. METHODS: Pooled semen from five prescreened human male donors was collected and evaluated for adequate motility prior to use. Ewes (n=6) were given a quick-dissolving tablet delivering active anti-sperm antibody, a placebo tablet, or phosphate-buffered saline (PBS) as a control measure. Coital simulation included mixing tablet/PBS in the sheep vagina for 5 minutes with 15 strokes with a test tube, instilling 1 mL of semen for 2 minutes, mixing with five test tube strokes, and retrieving the semen/drug/vaginal secretion mixture for microscopic examination. Progressively motile sperm were counted via video analysis for pooled and sheep samples, reported as #PMS/high powered field (hpf), and analyzed with ANOVA (P<.05 significant). RESULTS: Pooled semen had 13.4±3.1 PMS/hpf. Control sheep (PBS) had 3.7±2.6 PMS/hpf. Sheep given the antibody tablet had 0.04±0.05 PMS/hpf, whereas the placebo had 2.7±2.0 PMS/hpf (P<.001). The antibody tablet reduced the fraction of PMS by ∼99%. CONCLUSIONS/IMPLICATIONS: In clinical studies, less than 1.0 PMS/hpf has been a threshold for effective contraception; therefore, the results from this study indicate that suitably formulated tablets delivering anti-sperm antibody could serve as an effective nonhormonal contraceptive.

The evaluation of Naproxen Sodium Fast Dissolving Tablets emphasizes the critical role of careful formulation design and thorough testing in pharmaceutical development. Among the formulations, F7 demonstrated outstanding properties, including excellent flow characteristics and optimal tablet hardness. Stability testing over a four-week period showed consistent performance, though minor variations in tablet attributes were observed. Continuous monitoring is advised to ensure sustained efficacy. The in-vitro release profile revealed rapid disintegration and dissolution, crucial for prompt drug release. These results highlight the necessity of stringent quality control measures and ongoing optimization to enhance patient outcomes and ensure the reliability of Naproxen Sodium Fast Dissolving Tablets. In a parallel evaluation, the stability and performance of Naproxen Sodium Fast Dissolving Tablets were assessed under various environmental conditions, showing that temperature and humidity significantly impacted Naproxen Sodium concentration and dissolution rates. Formulation F7 emerged as the most promising, offering superior flow properties, compressibility, and dosage consistency. In-vitro tests confirmed rapid disintegration and dissolution, aligning with Pharmacopoeial standards. Four-week stability studies indicated consistent tablet characteristics, with only slight changes in hardness, friability, and drug content. Continued monitoring is recommended to ensure long-term stability and product quality. These findings underscore the importance of rigorous formulation optimization and stability testing to ensure reliable drug release and sustained efficacy. Keywords Naproxen Sodium Fast Dissolving Tablets, UV, HPLC, DSC, FT­IR